Ratio Therapeutics has entered into an agreement with the Medical Innovation Technology Management division of Wasatch Group to construct a radiopharmaceutical research and manufacturing facility in Salt Lake City, UT.
The organizations anticipate the 65,000-sq-ft facility to be fully operational in the second half of 2027.
The facility will have the capacity to scale manufacturing for future commercial needs as Ratio advances its candidates through clinical trials, the company said.
![A 53-year-old patient (patient number four) with a recurrent pituitary adenoma with extension of a cystic component of disease to the medial temporal lobe apparent on MRI (contoured in blue), and extension of disease to the left sphenoid bone and orbital apex apparent on [68Ga]Ga-DOTA-TATE (contoured in yellow).](https://img.auntminnie.com/mindful/smg/workspaces/default/uploads/2026/04/pituitary-tumor.QGsEnyB4bU.jpg?auto=format%2Ccompress&dpr=2&fit=crop&h=167&q=70&w=250)
